Application of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure

Objective To explore the clinical effect of metoprolol combined with trimetazidine in coronary heart disease patients with heart failure and improvement of cardiac function. Methods 160 coronary heart disease patients with heart failure were selected, and they were randomly divided into research group and control group according to the digital table, 80 cases in each group. The research group was treated with metoprolol combined with trimetazidine, and the control group was only treated with metoprolol therapy. The clinical curative effect, adverse reaction, heart rate(HR), plasma brain natriuretic peptide(BNP), left ventricular end-diastolic diameter(LVEDD), left ventricular end systolic diameter(LVESD) and left ventricular ejection fraction(LVEF) of the two groups were observed. Results The effective rate of the research group was 92.50%, which of the control group was 78.75%, the difference was statistically significant between the two groups(χ2=6.14, P 0.05), and after treatment, the HR and BNP were (72.53±4.24)beats/min, (221.42±11.42)pg/mL, (82.53±5.01)beats/min, (248.25±14.23)pg/mL respectively, the differences were statistically significant between the two groups(t=13.63, 13.15, all P 0.05); After treatment, the LVEDD, LVESD and LVEF of the two groups were (51.94±3.01)mm, (34.93±2.53)mm, (60.23±4.53)%, (58.23±3.21)mm, (41.21±2.49)mm, (53.23±4.64)% respectively, the differences were statistically significant between the two groups(t=12.78, 15.82, 9.66, all P 0.05). Conclusion The clinical effect of metoprolol combined with trimetazidine in the treatment of coronary heart disease patients with heart failure is obvious, and can improve heart function, it is worthy of clinical promotion. Key words: Heart failure; Metoprolol; Trimetazidine